As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Applied Therapeutics, Inc. The largest reported stake is T. Rowe Price Investment Management, Inc.'s, at 14.9%. 7 filings are on record since July 16, 2025 (Schedule 13G/A, November 14, 2025).
Sell to companies like Applied Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Vestal Point Capital, LP · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-02-17
- · Reporting person: Propel Bio Management, LLC · Sole voting: 6,015,394 · Shared voting: 0 · Sole dispositive: 6,015,394 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-12-31
- · Reporting person: Alexandria Real Estate Equities, Inc. · Sole voting: 0 · Shared voting: 6,500,000 · Sole dispositive: 0 · Shared dispositive: 6,500,000 · SCHEDULE 13G/A, 2025-12-15
- · Reporting person: T. Rowe Price Investment Management, Inc. · Sole voting: 21,403,300 · Shared voting: 0 · Sole dispositive: 21,403,300 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-11-14
- · Holder: T. Rowe Price Investment Management, Inc. · Percent: 13.2% · SCHEDULE 13G/A
Applied Therapeutics, Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-16. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 14.9% | 21,403,300 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Alexandria Real Estate Equities, Inc. | 4.3% | 6,500,000 | SCHEDULE 13G/A, 2025-12-15 | 2025-12-11 |
| Propel Bio Management, LLC | 4.2% | 6,015,394 | SCHEDULE 13G/A, 2025-12-31 | 2025-12-29 |
| BlackRock, Inc. | 3.7% | 5,219,475 | SCHEDULE 13G/A, 2025-07-16 | 2025-06-30 |
| The Vanguard Group | 3.34% | 4,734,013 | SCHEDULE 13G/A, 2025-07-29 | 2025-06-30 |
| Vestal Point Capital, LP | 0% | 0 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
Holding shares or following this stake? See who's behind Applied Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Applied Therapeutics, Inc. and the records around it.
Companies that share a holder
- Propel Bio Management, LLC also filed stake reports on 1 other company: Milestone Pharmaceuticals Inc. (Dec 2025)
- Vestal Point Capital, LP also filed stake reports on 27 other companies: Alto Neuroscience, Inc. (Aug 2026), iBio, Inc. (Aug 2026), Immunocore Holdings plc (Aug 2026)
- T. Rowe Price Investment Management, Inc. also filed stake reports on 167 other companies: CABALETTA BIO INC (Nov 2026), MADISON SQUARE GARDEN SPORTS CORP (Nov 2026), MSG RANGERS CORP (Nov 2026)
Watch Applied Therapeutics, Inc.
Get an email when Applied Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Applied Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Applied Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Applied Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 21,403,300 | 0 | 21,403,300 | 0 | SCHEDULE 13G/A, 2025-11-14 |
| Alexandria Real Estate Equities, Inc. | 0 | 6,500,000 | 0 | 6,500,000 | SCHEDULE 13G/A, 2025-12-15 |
| Alexandria Venture Investments, LLC | 0 | 4,450,000 | 0 | 4,450,000 | SCHEDULE 13G/A, 2025-12-15 |
| Alexandria Equities No. 7, LLC | 0 | 2,050,000 | 0 | 2,050,000 | SCHEDULE 13G/A, 2025-12-15 |
| Propel Bio Management, LLC | 6,015,394 | 0 | 6,015,394 | 0 | SCHEDULE 13G/A, 2025-12-31 |
| Leen Kawas | 6,015,394 | 0 | 6,015,394 | 0 | SCHEDULE 13G/A, 2025-12-31 |
| Richard Kayne and Suzanne Kayne Living Trust dtd 01/14/1999 | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-12-31 |
| Richard Kayne | 6,015,394 | 0 | 6,015,394 | 0 | SCHEDULE 13G/A, 2025-12-31 |
| Propel Bio Partners LLC | 6,015,394 | 0 | 6,015,394 | 0 | SCHEDULE 13G/A, 2025-12-31 |
| Vestal Point Capital, LP | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-17 |
| Ryan Wilder | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-02-17 |
The latest filing names Applied Therapeutics, Inc., with its principal executive office as 545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY 10017 (SCHEDULE 13G/A, 2026-02-17).
What the percentages are based on
Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the shares of common stock of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.Alexandria Real Estate Equities, Inc., SCHEDULE 13G/A, 2025-12-15
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-16 | BlackRock, Inc. | 3.7% | SCHEDULE 13G/A |
| 2025-07-29 | The Vanguard Group | 3.34% | SCHEDULE 13G/A |
| 2025-08-14 | T. Rowe Price Investment Management, Inc. | 13.2% | SCHEDULE 13G/A |
| 2025-11-14 | T. Rowe Price Investment Management, Inc. | 14.9% | SCHEDULE 13G/A |
| 2025-12-15 | Alexandria Real Estate Equities, Inc. | 4.3% | SCHEDULE 13G/A |
| 2025-12-31 | Propel Bio Management, LLC | 4.2% | SCHEDULE 13G/A |
| 2026-02-17 | Vestal Point Capital, LP | 0% | SCHEDULE 13G/A |
Questions about who owns Applied Therapeutics, Inc.
Who owns Applied Therapeutics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Applied Therapeutics, Inc.: T. Rowe Price Investment Management, Inc. (14.9%, Schedule 13G/A, filed 2025-11-14).
When did T. Rowe Price Investment Management, Inc. buy into Applied Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from T. Rowe Price Investment Management, Inc. on this page is the Schedule 13G/A, filed 2025-08-14, reporting 13.2%; its latest, Schedule 13G/A filed 2025-11-14, reports 14.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Applied Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.